HUDDINGE, Sweden, May 3, 2019 /PRNewswire/ --January – March Significant events during the quarter The phase II study of birinapant in combination with Keytruda® in colorectal cancer patients progresses according to plan. A futility analysis is planned to be conducted no later than the...
from PR Newswire: http://bit.ly/2Y6PJ7H
No comments:
Post a Comment